Massicotte H, Rauch J, Shoenfeld Y, Tannenbaum H
Hybridoma. 1984 Fall;3(3):215-22. doi: 10.1089/hyb.1984.3.215.
The utilization of one human lymphoblastoid cell line in fusion experiments with peripheral blood lymphocytes from patients with systemic lupus erythematosus (SLE) has made it possible to define efficient and reproducible conditions for the production of anti-DNA-secreting human-human hybridomas. This investigation, using the human lymphoblastoid cell line GM 4672 fused in the presence of 44% polyethylene glycol with lymphocytes from SLE patients, demonstrated a maximal yield of 22.8% hybridomas, 17% of which produced anti-DNA antibodies. We were able to define, in two independent laboratories, that the maximal yield of hybridomas occurred when the lymphocyte to GM 4672 cell ratio was 1:1 and cells were seeded in 2.0 ml wells at a concentration of 4 X 10(5) cells/well. This report demonstrates the reproducibility of human-human hybridoma production with the GM 4672 cell line and the establishment of efficient conditions for the production of anti-DNA autoantibodies from SLE patients.
利用一种人类淋巴母细胞系与系统性红斑狼疮(SLE)患者的外周血淋巴细胞进行融合实验,已能够确定产生分泌抗DNA的人-人杂交瘤的有效且可重复的条件。本研究使用人类淋巴母细胞系GM 4672在44%聚乙二醇存在下与SLE患者的淋巴细胞融合,结果显示杂交瘤的最大产量为22.8%,其中17%产生抗DNA抗体。我们能够在两个独立实验室中确定,当淋巴细胞与GM 4672细胞的比例为1:1且细胞以4×10⁵个细胞/孔的浓度接种于2.0 ml孔中时,杂交瘤的产量最高。本报告证明了使用GM 4672细胞系生产人-人杂交瘤的可重复性,以及为从SLE患者产生抗DNA自身抗体建立了有效的条件。